九一升白口服液在^(131)I治疗伴WBC减少Graves病的应用  

Effects of 91-WBC Increasing Drinks on Leukopenia in Graves Disease Patients Received ^(131)I Therapy

作　　者：胡兴荣 吴献华[2] 胡启托 崔显念 徐先早 

机构地区：[1]湖北省恩施自治州中心医院影像科,445000 [2]湖北省恩施自治州中心医院血液内科,445000 [3]湖北民族学院医学院 [4]湖北省恩施自治州中心医院核医学科,445000

出　　处：《中华全科医学》2008年第8期797-798,共2页Chinese Journal of General Practice

摘　　要：目的评价九一升白口服液在131I治疗伴WBC减少Graves病(GD)患者的临床安全性及治疗效果。方法GD伴WBC减少(外周血WBC<4.0×109/L)患者97例,根据运用升高WBC药物不同随机分为2组:治疗组给予九一升白口服液+131I,对照组给予鲨肝醇、维生素B4和利血生+131I;根据甲状腺大小、最高摄131I率、甲状腺功能亢进症(简称甲亢)病程及年龄,常规方法确定131I治疗剂量;治疗后定期复查外周血象和甲状腺功能,随访6~12个月。结果97例患者131I治疗后甲状腺功能恢复正常70例,功能改善15例,功能减退8例,无效4例。患者外周血WBC较治疗前增加,各组治疗前后WBC差异均有统计学意义(P<0.05),但治疗组较对照组回升快而明显(P<0.05)。结论九一升白口服液在131I治疗伴WBC减少GD安全、有效,九一升白口服液是一种较理想的升高WBC的治疗药物。Objective To evaluate clinical safety and effects of 91-WBC increasing drinks on the leukopenia in Graves disease （GD） patients received ^131I therapy. Methods 97 GD patients with leukopenia were randomly divided into treatment group and control group, ^131I and 91-WBC increasing drinks were administrated to the treatment group;batiolum,VitB4 and leucogen to control group. The dose of ^131I were determined according to thyroid volume, the highest ^131I uptake rate of thyroid, hyperthyroidism course and patients age. Thyroid function and periphery hemogram of the treated patients were regularly rechecked and the follow up was 6 - 12 months. Results Among 97 patients, the function of thyroid was recovered in 70 cases,improved in 15 cases, decreased in 8 cases and ineffective in 4 cases. There was significant difference in WBC counts before and after the treatment（P 〈 0.05 ）. Periphery WBC counts of treat group increased more than that of control group （ P 〈 0.05 ）. Conclusions 91-WBC increasing drinks combined with ^131I were safe and effective for GD patients with leukopenia. 91-WBC increasing drinks can increase WBC obviously.

关 键 词：GRAVES病 白细胞减少症 ^131碘 九一升白口服液 

分 类 号：R581.11[医药卫生—内分泌]